OPEN END TURBO CALL-OPTIONSSCHEIN MIT SL - MODERNA | Delayed Deutsche Boerse AG 11:29:39 15/05/2024 pm IST | ||
| 6.39 EUR | 0.00% |
|
| Current month | +29.35% | ||
| 1 month | +44.24% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
| Date | Price | Change |
|---|---|---|
| 15/24/15 | 6.39 | 0.00% |
| 14/24/14 | 6.39 | +1.91% |
| 13/24/13 | 6.27 | +13.79% |
| 10/24/10 | 5.51 | -9.08% |
| 09/24/09 | 6.06 | +1.68% |
Delayed Quote Deutsche Boerse AG
Last update May 15, 2024 at 11:29 pm IST
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
Société Générale
|
| WKN | SB0Z1C |
| ISIN | DE000SB0Z1C9 |
| Date issued | 08/06/2020 |
| Strike | 58.35 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.51 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 38.57 € |
|---|---|
| Lowest since issue | 0.89 € |
| Spread | 0.02 € |
| Spread % | 0.31% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
128.3
USD
Average target price
138.5
USD
Spread / Average Target
+7.94%
- Stock Market
- Certificates
- Certificat
